RecruitingPhase 1NCT06364852

An Evaluation of LY007 Cell Injection for r/r B-NHL

An Evaluation of LY007 Cell Injection for Recurrent/Refractory CD20 Was Positive Tolerability, Safety, and Efficacy of B-cell Non-Hodgkin Lymphoma in Open, Single-arm Stage I Clinical Research

Sponsor

Ruijin Hospital

Enrollment

18 participants

Start Date

Dec 25, 2021

Study Type

INTERVENTIONAL

Conditions

B-NHL

Summary

An evaluation of LY007 cell injection for recurrent/refractory CD20 was positive Tolerability, safety, and efficacy of B-cell non-Hodgkin lymphoma in open, single-arm Phsea I Clinical research

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study tests LY007, a CAR-T cell therapy (a type of immune cell therapy engineered to attack cancer), for people with relapsed or treatment-resistant B-cell non-Hodgkin lymphoma (a type of blood cancer) that tests positive for the CD20 protein. **You may be eligible if...** - You are between 18 and 70 years old - You have been confirmed to have CD20-positive B-cell non-Hodgkin lymphoma (including diffuse large B-cell lymphoma or transformed follicular lymphoma) - Your cancer has returned or did not respond to prior treatment - Your general health is acceptable (ECOG 0–1) - Your expected survival is more than 3 months **You may NOT be eligible if...** - Your lymphoma does not express CD20 - You have other serious medical conditions affecting eligibility - Your cancer type is not covered by this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.